Background: Previous meta-analyses evaluating the effectiveness of individual dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of heart failure (HF) were limited because of the small number of trials with direct comparisons between two treatments. Methods: A Bayesian network meta-analysis was performed to investigate the relationship between DPP-4 inhibitors and the risk of HF in patients with type-2 diabetes mellitus. The primary outcome was the occurrence of HF or hospital admission for HF. Results: Fifty randomized controlled trials were identified. Relative to placebo, no increased risk of HF events was seen for vildagliptin (risk ratio [RR] 0.71; 95% confidence interval [CI] 0.25-1.68), sitagliptin (RR 0.86; CI 0.43-1.57), or saxagliptin (RR 0.84; 95% CI 0.33-1.61), but alogliptin was associated with a higher risk of HF (RR 2.13; 95% CI 1.06-6.26). Vildagliptin and sitagliptin were associated with a significantly decreased risk of HF compared with alogliptin. Vildagliptin had the highest probability to be the safest option with regard to the risk of HF (49.18%), followed by saxagliptin (26.56%), sitagliptin (20.76%), linagliptin (0.25%), and alogliptin (0.12%). A statistically significant inconsistency was noted in some comparisons. Conclusions: The risk of HF needs to be taken into account when prescribing DPP-4 inhibitors. Evidence suggests that vildagliptin may be the least harmful agent with regard to the risk of HF. However, a statistically significant inconsistency was identified in the Bayesian network meta-analysis. Therefore, further studies are warranted to evaluate the cardiovascular safety of DPP-4 inhibitors.
Introduction
Dipeptidyl peptidase-4 (DPP-4) inhibitors play a broad and important role in the management of patients with type 2 diabetes mellitus (type 2 DM). However, controversy regarding the safety of DPP-4 inhibitors, along with the evidence of an increased risk of heart failure (HF), has focused attention on the use of DPP-4 inhibitors for the type 2 DM population with heart failure (HF) [1, 2] . In this context, clinicians are concerned about the risk of HF differing across DPP-4 inhibitors.
Although some meta-analyses were performed to evaluate the HF risk associated with the DPP-4 inhibitors, their conclusions were limited because of the small number of trials with direct comparisons between two treatments [3, 4] . For instance, in a meta-analysis by Kongwatcharapong et al., the authors concluded that saxagliptin was associated with an increased risk of HF, whereas no significant difference was observed with other individual DDP-4 inhibitors [3] . Thus, only seven studies were included in evaluating the HF risk of linagliptin, which resulted in an uncertainty of the evidence base. These studies also failed to integrate all available randomized controlled trials into a single analysis, and this did not allow for adequate assessment of the comparative effectiveness of all treatments.
Network meta-analysis, a new and validated statistical methodology, allows for comparing the effectiveness of all treatments, especially when some treatments have not been compared head to head. For instance, by obtaining information from a trial comparing saxagliptin with placebo and another comparing linagliptin with placebo, an indirect estimate of the effectiveness of saxagliptin to linagliptin can be achieved. Therefore, we aim to perform a Bayesian network meta-analysis here to evaluate the risk of HF among all DPP-4 inhibitors.
Methods
This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement [5] . Searches of PubMed, Web of Science, the Cochrane library, Clinicaltrial.gov, Clinicaltrialresults.org, and reference lists of relevant articles from inception to February 2016. The keywords searched were as follows: "diabetes mellitus type 2," "randomized controlled trial," "dipeptidyl peptidase-4 inhibitors (including alogliptin, linagliptin, sitagliptin, saxagliptin, and vildagliptin)."
We included studies if 1) the recruited population comprised patients with type 2 DM; 2) the intervention was with DPP-4 inhibitors, including alogliptin, linagliptin, sitagliptin, saxagliptin, and vildagliptin; 3) comparators were DPP-4 inhibitors, other hypoglycemic agents, and placebo; 4) the studies reported any occurrence of HF or hospital admission for HF; 5) the studies were randomized controlled trials (RCTs); 6) the studies were published in English. We excluded studies with zero events in both groups because these comparisons provide no information on treatment effect. To reach a consensus, a divergence of views was resolved by joint review of the literature.
Two independent investigators (W.G., Q.S.) reviewed the full text of eligible studies and extracted the relevant information. If different results were noted in the same trial, we extracted the most recent data for analysis. In some trials, if the DPP-4 inhibitors were sequentially used with another drug, we collected the data about the treatment before the switching occurred. The primary outcome was the occurrence of HF or hospital admission for HF, which was defined according to the individual trials. Intention-to-treat sample sizes were used when they were available. The Cochrane risk-of-bias tool was used to assess the risk of bias for RCTs [6] .
We used the random effects model for the Bayesian network meta-analysis because it assumes and accounts for unexplained heterogeneity [7, 8] . We used vague priors with uniform prior (0-2) distributions for parameters, such as means and standard deviations. All outcomes were expressed as risk ratios (RRs) and its corresponding 95% confidence intervals (CIs). Additionally, the analysis was done by using the Markov chain Monte Carlo methods [7] . Four chains were suitable, yielding 400,000 iterations (100,000 per chain) generating the posterior distributions of the model parameters. Convergence was checked by using the Brooks-Gelman-Rubin diagnostic [9] . The goodness of fit of the model was assessed by calculating residual deviance [10] . The I 2 statistic was used to investigate the possibilities of statistical heterogeneity [11, 12] . To assess inconsistency, we carried out the "node splitting" approach to calculate the Bayesian P value [11] . In addition, we evaluated rank probabilities to determine the probability of each treatment being the best in terms of safety outcome [13] . To explore the association between log-risk of HF and the length of study follow-up, we performed a metaregression analysis, wherein treatment effects relative to placebo were allowed to depend on the study follow-up through a single interaction term [14] . Sensitivity analysis was performed by excluding the trials in which the outcome was hospital admission for HF. Additionally, we created a comparison-adjusted funnel plot to detect the presence of any publication bias [13, 15] . The Bayesian frame network meta-analysis was conducted by using R software (version 3.2.0), and further analysis was conducted by STATA 12.0. (The R code is shown in the Supplementary Appendix).
Results
Finally, 50 trials were included in the network meta-analysis (Supplementary Table 1 ). The PRIMA flow chart is shown in Supplementary Figure 1 . The characteristics of the included studies and their quality assessment are shown in Supplementary Table 2 . The following options were tested in the network: saxagliptin, sitagliptin, alogliptin, vildagliptin, linagliptin, placebo, and active comparison. Active comparators included metformin, glipizide, gliclazide, glimepiride, canagliflozin, empagliflozin, pioglitazone, albiglutide, and liraglutide. We regarded these agents as active comparators rather than the type of the hypoglycemic agents (e.g., sodium glucose cotransporter 2) because they were not therapy options that we focused on in our network meta-analysis. Therefore, we combined all these hypoglycemic agents into one active comparator, which was important for making a connected network. The network plot is given in Figure 1 .
The results are shown in Table 1 The probability ranking of each treatment is shown in Supplementary Table 3 . Vildagliptin had the highest probability to be the safest option with regard to the risk of HF (49.18%), followed by saxagliptin (26.56%), sitagliptin (20.76%), linagliptin (0.25%), and alogliptin (0.12%).
The global heterogeneity parameter I 2 values were 0%
(Supplementary Figure 2) . A statistically significant inconsistency was identified in the Bayesian framework (Supplementary Figure 3) . Bayesian meta-regression analyses showed no significant effect of the study follow-up time (regression coefficient 0.35; CI -0.56 to 1.25). The results of the sensitivity analysis were mostly similar to the results of the main analysis (Supplementary Table 4 ). The comparison-adjusted funnel plots of the network meta-analysis were not suggestive of any publication bias (Supplementary Figure 4) .
Discussion
To the best of our knowledge, this is the first network metaanalysis to review the safety of different DPP-4 inhibitors on HF Fig. 1 -Network plot for the Bayesian network metaanalyses.
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outcomes in patients with diabetes. We found that alogliptin is the only agent with a significantly increased risk of HF compared with placebo, and no signals were detected with other therapy options. Relative to alogliptin, sitagliptin and vildagliptin were associated with a lower risk of HF. Therapy with alogliptin seemed the most harmful across all the DPP-4 inhibitors, and vildagliptin had the highest probability to be the safest option with regard to the risk of HF.
There is a well-established epidemiologic link between DM and HF. Compared with patients without diabetes, those with diabetes were much more likely to develop chronic HF [16] . Therefore, controlling the risk factors of HF was emphasized in the management of type 2 DM. In our network meta-analysis, alogliptin was the only therapy option to have a higher risk of HF compared with placebo and seemed the most harmful therapy across all the DPP-4 inhibitors, suggesting that the HF risk needs to be taken into account when prescribing any DPP-4 inhibitors, especially for patients with diabetes who have pre-existing HF.
Some studies were performed to evaluate the effect of individual DPP-4 inhibitors on HF [3, 4, 17, 18] . Their results showed that vildagliptin was not associated with an increased risk of HF compared with placebo, which was consistent with the result of our network meta-analysis [17] . However, we were able to provide a formal rank order for treatment strategies with respect to the HF risk. Our results demonstrated that vildagliptin had a higher probability of being at a superior ranking position, suggesting that vildagliptin is the least harmful in terms of HF risk. An observational study, conducted by Fu et al., evaluated the risk of hospitalization for HF differed across DPP-4 inhibitors by examining the association between hospitalization for HF and treatment with saxagliptin versus sitagliptin [19] . Their results showed that saxagliptin is not associated with an increased risk of HF compared with sitagliptin. However, the poor estimate of comparison between other DPP-4 inhibitor drugs (e.g., vildagliptin versus alogliptin) could not be obtained in that study because of the complexity of pharmacoepidemiologic studies. In this study, we assessed the cardiovascular safety of the DPP-4 inhibitors using the Bayesian network meta-analysis. We were able to integrate all evidence into one analysis, drawing on both direct comparisons within trials and indirect comparisons across trials via common a comparator, resulting in a gain of statistical precision compared with previous meta-analyses [20] . In addition, our study allowed a unified analysis of all randomized evidence to compare individual DPP-4 inhibitors head to head, which has rarely or never been done in an RCT. In agreement with previous studies, our meta-analysis demonstrated no association between saxagliptin and HF compared with sitagliptin. Nevertheless, sitagliptin and vildagliptin were associated with a lower risk of HF compared with alogliptin, which suggested a differential effect of each DPP-4 inhibitor on the risk of HF.
Our study has some limitations. First, in some trials, DPP-4 inhibitors were used in combination with other antihyperglycemic drugs, which made it challenging to determine a direct link between DPP-4 inhibitors and HF risk. Second, the presence of several factors (e.g., drug doses and definitions of HF in the studies included in the analysis) that could potentially increase the degree of heterogeneity among the studies. Because no relevant information was available, a meta-regression or subgroup analysis was not performed to explore these factors. Nevertheless, we used the random effect model to overcome the constraint of common variance among trials. Third, network inconsistency was noted in some poor analyses that included active comparator versus alogliptin, placebo versus alogliptin, and placebo versus active comparator. The reasons for the inconsistency may be the extremely low incidence of HF and the small number of the head-to-head studies [21] . In our network meta-analysis, relative to alogliptin, the active comparator and placebo showed a trend to decrease the risk of HF (RR 0.44; 95% CI 0.13-1.30 and RR 0.88; 95% CI 0.43-1.50), respectively. The effect estimated from indirect comparison showed that the placebo had a lower HF risk compared with the active comparator (RR 0.44; 95% CI 0.20-0.90). However, placebo was significantly superior to the active comparator from the only three direct evidence (RR 1.3 Â 10 -9
; 95% CI 6.20 Â 10 -29 -0.11), which was not consistent with the results from indirect evidence. In short, a small number of studies comparing the active comparator versus placebo and the extremely low incidence of HF may have affected network consistency in those comparisons. Thus, the results of the network meta-analysis should be interpreted cautiously. Overall, our study suggests that the HF risk needs to be taken into account when using DPP-4 inhibitors for patients with type 2 DM. Evidence suggests that differences exist among individual DPP-4 inhibitors and that vildagliptin seems to be the least harmful with regard to the risk of HF. Nevertheless, our results Comparisons should be read from left to right. The estimate is located at the intersection of the treatments in the column heads and the treatments in the row heads. An RR value 41 favors the column-defining treatment. An RR value o1 favors the row-defining treatment.
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 1 4 2 7 -1 4 3 0 should be interpreted with caution, since some limitations are present. Hence, large RCTs with prespecified, well-defined safety outcomes are warranted to assess the impact of DPP-4 inhibitors on HF outcomes.
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